ABIVAX
Clinical-stage biotech developing therapeutics for chronic inflammatory diseases.
ABVX | PA
Overview
Corporate Details
- ISIN(s):
- FR0012333284 (+1 more)
- LEI:
- 969500D8TMNB184OJU95
- Country:
- France
- Address:
- 7 BOULEVARD HAUSSMANN, 75009 PARIS
- Website:
- https://www.abivax.com
- Sector:
- Manufacturing
Description
Abivax is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases by regulating the immune system. The company's scientific approach is centered on harnessing microRNA (miRNA) biology. Its lead drug candidate, obefazimod, is an investigational, once-daily, oral small molecule with a novel mechanism of action that enhances the expression of miR-124, a natural regulator of the inflammatory response. The primary development program for obefazimod focuses on ulcerative colitis, for which the company has reported positive Phase 3 clinical trial results. Abivax is also investigating the candidate for the treatment of Crohn's disease and other inflammatory conditions, while exploring follow-on compounds.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-07-23 22:15 |
Abivax annonce le lancement d’une offre au public
|
French | 230.0 KB | ||
| 2025-07-23 22:15 |
Abivax annonce le lancement dune offre au public
|
French | 43.8 KB | ||
| 2025-07-22 22:06 |
Abivax annonce des résultats positifs de phase 3 pour les deux essais d'inducti…
|
French | 353.2 KB | ||
| 2025-07-22 22:06 |
Abivax annonce des resultats positifs de phase 3 pour les deux essais d'inducti…
|
French | 104.2 KB | ||
| 2025-07-17 18:00 |
ABIVAX: Nombre d’actions composant le capital social et nombre total de droits …
|
French | 115.5 KB | ||
| 2025-07-17 18:00 |
ABIVAX: Nombre dactions composant le capital social et nombre total de droits d…
|
French | 20.7 KB | ||
| 2025-06-19 18:00 |
ABIVAX: Nombre d’actions composant le capital social et nombre total de droits …
|
French | 114.5 KB | ||
| 2025-06-19 18:00 |
ABIVAX: Nombre dactions composant le capital social et nombre total de droits d…
|
French | 20.7 KB | ||
| 2025-06-19 16:13 |
Franchissement de seuil
|
French | 115.2 KB | ||
| 2025-06-11 22:00 |
Abivax Announces Results of its June 6, 2025 Annual General Meeting
|
English | 106.1 KB | ||
| 2025-06-11 22:00 |
Abivax annonce les résultats de son Assemblée Générale du 6 juin 2025
|
French | 81.2 KB | ||
| 2025-06-11 22:00 |
Abivax Announces Results of its June 6, 2025 Annual General Meeting
|
English | 10.1 KB | ||
| 2025-06-10 15:06 |
Franchissements de seuils
|
French | 130.6 KB | ||
| 2025-06-02 22:00 |
Abivax présente ses résultats financiers du premier trimestre 2025
|
French | 276.0 KB | ||
| 2025-06-02 22:00 |
Etats financiers consolidés condensés intermédiaires (non audités) au 31 mars 2…
|
French | 5.5 MB |
Automate Your Workflow. Get a real-time feed of all ABIVAX filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ABIVAX
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ABIVAX via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-07-11 | N/A | Other | Buy | 319,107 | N/A |
| 2024-03-01 | N/A | Other | Buy | 7,000 | 91,557.90 EUR |
| 2023-12-19 | N/A | Other | Sell | 50,000 | 482,500.00 EUR |
| 2023-12-11 | N/A | Other | Sell | 2,062 | 19,382.80 EUR |
| 2023-11-13 | N/A | Other | Buy | 4 | 39.84 EUR |
| 2023-07-13 | N/A | Other | Sell | 192,781 | 3,101,480.01 EUR |
| 2023-03-27 | N/A | Other | Other | 38,461 | 249,996.50 EUR |
| 2023-02-27 | N/A | Other | Other | 1,535,000 | 9,977,500.00 EUR |
Peer Companies
